Roggwil, May 9, 2023 – In record time, the first series of the tinnitus therapy device tinniwell for the Asian market was produced and will be delivered this month. The management of Resaphene is currently negotiating with other medical technology distributors for the grant of additional country licenses. Since the markets no longer need to be developed independently, sales growth can increase exponentially.

++ About Resaphene Suisse AG

Resaphene Suisse AG, based in Roggwil, Switzerland, is a medical technology company that was founded in 2015 and has been selling a tinnitus therapy device under the name tinniwell since 2016.

++ Contact for inquiries:

Resaphene Suisse AG
Ms. Anke Rauterkus (Chief Executive Officer)
Bahnhofplatz 5
9322 Egnach
Switzerland

T. +41 714500668
a.rauterkus@resaphene.ch